Skip to content

Respiratory Muscle Endurance Training in Healthy Elderly

Effects of Respiratory Muscle Endurance Training on Blood Pressure, Exercise Performance and Sleep Quality in Healthy Elderly

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03730935
Acronym
RETE
Enrollment
24
Registered
2018-11-05
Start date
2018-12-07
Completion date
2019-05-24
Last updated
2019-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Prevalence of hypertension in the elderly is high. Given that hypertension is the leading cause of cardiovascular disease worldwide, safe and efficacious treatment options for this condition are highly desired. Apart from medication, changes in lifestyle are recommended to lower blood pressure, such as an increase in physical exercise. However, whole-body exercise is not feasible for all. Mobility disabilities, for example, increase sharply with age and are already common in middle age. For this population, it is necessary to have alternative, non-invasive interventions with similar effects on blood pressure. One such intervention might be respiratory muscle endurance training (RMET), but the effects on blood pressure are currently unknown. The primary aim of this project is therefore to investigate the effects of RMET over the course of several weeks on resting blood pressure in healthy elderly. The secondary aim of the project is to evaluate the effects of RMET on uphill exercise performance in healthy active elderly given that elderly experience structural and functional changes of the lungs potentially affecting exercise performance. Finally, since prevalence of subjective sleep complaints is also high in the elderly, the present study will also investigate the effects of RMET on sleep quality.

Interventions

Respiratory muscle endurance training performed over the duration of 4 weeks

Sponsors

Swiss Federal Institute of Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
55 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Age: 55-80 years * Active (according to World Health Organisation Criteria) * Systolic blood pressure lower than 140 mmHg and diastolic blood pressure lower than 90 mmHg * Non-smoking * Body-Mass-Index (BMI): 18.5-29.9 kg·m-2 * Normal lung function

Exclusion criteria

* Known or suspected non-compliance, drug or alcohol abuse * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * Previous enrolment into the current study * Enrolment of the investigator, his/her family members, employees and other dependent persons * Intake of blood pressure medication or history of hypertension * Intake of medications affecting sleep or the performance of the respiratory, cardiovascular or neuromuscular system * Acute illness or chronic conditions affecting sleep or the performance of the respiratory, cardiovascular or neuromuscular system

Design outcomes

Primary

MeasureTime frameDescription
Blood pressureAt baseline and after completion of the study (approximately one month)Change in systolic and diastolic blood pressures (in mmHg) between baseline and after one month of training. Measurements will be done in triplicate after at least 10 minutes of quiet lying on a stretcher

Secondary

MeasureTime frameDescription
Endurance capacity testAt baseline and after completion of the study (approximately one month)Change in exercise performance assessed with an endurance capacity test (time to exhaustion, in minutes). The test will be conducted on a motorised treadmill.
Sleep efficiencyAt baseline between visits 1-2 and after completion of the study (approximately one month) at visits 4-5Change in sleep efficiency assessed with an actigraph device measuring sleep efficiency (in %), . Measurements will be done during the nights between the two baseline visits and between the two post visits
Sleep onset latencyAt baseline between visits 1-2 and after completion of the study (approximately one month) at visits 4-5Change in sleep onset latency assessed objectively with an actigraph device measuring sleep onset latency (in min). Measurements will be done during the nights between the two baseline visits and between the two post visits
Incremental testAt baseline and after completion of the study (approximately one month)Change in exercise performance assessed with an incremental test to exhaustion (maximal oxygen consumption in ml· min-1· kg-1). The test will be conducted on a motorised treadmill.
Oxygen saturation during the nightAt baseline between visits 1-2 and after completion of the study (approximately one month) at visits 4-5Change in oxygen saturation assessed objectively with a wrist-worn pulse oximeter measuring oxygen saturation (in %). Measurements will be done during the nights between the two baseline visits and between the two post visits
Heart rate during the nightAt baseline between visits 1-2 and after completion of the study (approximately one month) at visits 4-5Change in heart rate assessed objectively with a wrist-worn pulse oximeter measuring heart rate (in 1·min-1). Measurements will be done during the nights between the two baseline visits and between the two post visits
Subjective sleep qualityAt baseline between visits 1-2 and after completion of the study (approximately one month) at visits 4-5Change in subjective sleep quality (i.e. How well did you sleep? and How recovered are you?) measured at home after each intervention with a visual analog scale (VAS). The two VAS consists each of a 10cm-horizontal line, with the left end of the lines representing low sleep quality (slept very badly and not recovered at all, respectively) and the right end representing good sleep quality (slept very well and completely recovered, respectively). Participants are asked to draw a vertical line in between the two ends on each of the two VAS.
Fragmentation indexAt baseline between visits 1-2 and after completion of the study (approximately one month) at visits 4-5Change in fragmentation index assessed objectively with an actigraph device measuring fragmentation index (unitless). Measurements will be done during the nights between the two baseline visits and between the two post visits

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026